MAP2K7 and neoplasm: These clusters include #0 second-line therapy, #1 potential synergistic anti-tumor activity, #2 controlled trial, #3 programmed death-ligand, #4 treatment perspective, #5 PD-1 blockade, #6 muscle volume loss, #7 non-viral unresectable hepatocellular carcinoma, #8 co-delivery of MEK inhibitors, #9 hepatocellular carcinoma patient, #10 adverse event, #11 dual programmed death receptor-1, and #12 hepatocellular carcinoma.